Europe to Set Criteria for Measuring Therapeutic Innovation by the end of 2017

The National Congress of Hospitals and Health Management reviewed the Access to Medicines in the European Union report which looks to provide new categorisation for innovation which will be more binding, starting with the definition of what added therapeutic value and how it is evaluated. In addition, it is necessary to include the concept of effectiveness and measure it when the drug is already marketed. With this, the following is to make a classification of the levels of innovation and the therapeutic value with respect to what already exists in the market.

For more information, click here.

Tagged with

Published on 3. April 2017 in News EU